Financials • Cartesian Therapeutics

RNAC

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

12/2014

10 financials

12/2024

Year	Revenue	EBITDA	Net Inc	Net Mrg	Equity	ROE	Net Debt	ND/EBITDA	OCF SBC	Capex	FCF	Free SBC	EPS
12/2015	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2016	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2017	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2018	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2019	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2022	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2023	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2024	39	-76	-77	L	-7	L	-199	-	-30	-9	168	-39	L

To see all financials—including updated, you must be Premium.